Recombinant Human G-protein coupled receptor 1 (GPR1)

What is GPR1 and what is its biological function?

GPR1 is a member of the Class B or secretin receptor-like family of G protein-coupled receptors (GPCRs). It functions as a receptor for the chemoattractant adipokine chemerin/RARRES2, suggesting a role in the regulation of inflammation and energy homeostasis . It signals mainly via the beta-arrestin pathway, but binding of RARRES2 also weakly activates G proteins, calcium mobilization, and MAPK1/MAPK3 phosphorylation .

The mature extracellular domain (ECD) of human GPR1 shares significant amino acid identity with mouse and rat GPR1. It is expressed in pancreas, lung, heart, kidney, hypothalamus, and stomach . Recent research has shown that GPR1 is capable of Gi signaling when stimulated with full-length chemerin or its C-terminal nonapeptide (C9, YFPGQFAFS) .

What expression systems are recommended for producing recombinant human GPR1?

Several expression systems can be used to produce recombinant human GPR1:

For functional studies, the wheat germ expression system with proprietary liposome technology has been successfully used to produce full-length human GPR1 (NP_005270.2) without tags . This system is particularly suitable for GPCRs as it can incorporate them directly into liposomes, maintaining their native structure.

How should researchers design experiments to study GPR1 signaling pathways?

When designing experiments to study GPR1 signaling pathways, researchers should follow these methodological steps:

• Define your variables clearly :

  • Independent variable: GPR1 ligand (e.g., chemerin or C9 peptide concentration)

  • Dependent variable: Measure of receptor activation (e.g., cAMP levels, calcium flux, ERK phosphorylation)

  • Control variables: Cell type, expression levels, temperature, incubation time

• Select appropriate experimental controls:

  • Positive control: Known GPR1 activator (chemerin)

  • Negative control: Untransfected cells or cells with mutated GPR1

  • Vehicle control: Buffer solution without ligand

• Choose a suitable receptor activation assay:

  • For Gi protein coupling: cAMP inhibition assay

  • For β-arrestin recruitment: BRET or FRET-based assays

  • For downstream signaling: ERK1/2 phosphorylation assay

• Implement a robust study design:

  • Dose-response experiments (10^-12 to 10^-6 M ligand)

  • Time-course experiments (30 sec to 60 min post-stimulation)

  • Signal specificity experiments using inhibitors of specific pathways

Remember that the study design should be "the architecture of an experimental study and a description of how the study was conducted, including all elements of how the data were obtained" .

What methods are available for studying GPR1-ligand interactions?

Several complementary techniques can be employed to study GPR1-ligand interactions:

• Binding assays:

  • Radioligand binding using [125I]-labeled chemerin

  • Fluorescence-based binding assays using fluorescently labeled ligands

  • Surface plasmon resonance (SPR) to measure binding kinetics

• Structural studies:

  • Cryo-EM has been successfully used to determine the structure of GPR1 bound to chemerin and C9 peptide

  • X-ray crystallography (challenging for GPCRs but possible with stabilizing mutations)

  • NMR for studying specific domains or peptide interactions

• Computational approaches:

  • Molecular dynamics simulations to analyze binding energetics

  • Free energy landscape estimation by parallel bias metadynamics

  • Molecular docking studies to predict binding poses of novel ligands

• Site-directed mutagenesis:

  • Alanine scanning mutagenesis to identify critical binding residues

  • Point mutations introduced using homologous recombination

  • Structure-guided mutations based on cryo-EM data

Recent research has employed parallel bias metadynamics simulations to estimate the unbinding free energy landscape of the C-terminus of chemerin in both C9-GPR1 and full-length chemerin-GPR1 complexes , providing valuable insights into the energetics of these interactions.

How does the "two-site" binding model of chemerin to GPR1 work, and what are its implications?

The "two-site" binding model of chemerin to GPR1 represents a sophisticated binding mechanism that has significant implications for drug development. According to recent cryo-EM studies , this model works as follows:

• C-terminal engagement (Site 1):

  • The C-terminal nonapeptide (C9, YFPGQFAFS) of chemerin inserts into the transmembrane (TM) binding pocket

  • This insertion is both necessary and sufficient for GPR1 signaling

  • C9 alone can activate GPR1, demonstrating the functional importance of this interaction

• N-terminal core interactions (Site 2):

  • The bulky N-terminal core of full-length chemerin interacts with a β-strand located at the N-terminus of GPR1

  • This interaction involves multiple β-strands of full-length chemerin, forming a β-sheet

  • This β-sheet serves as a "lid" for the TM binding pocket

• Energetic considerations:

  • Molecular dynamics simulations with free energy landscape analysis indicate that removing the β-sheet "lid" is energetically expensive

  • This suggests a stabilizing role for the N-terminal interaction, potentially leading to prolonged receptor activation

Implications:

• The dual binding mode may allow for more selective drug design targeting either site

• C9 peptide derivatives could serve as lead compounds for developing more potent and selective GPR1 modulators

• Understanding this binding model helps explain why C9 is an activating peptide at GPR1 and how full-length chemerin enhances interaction with GPR1

What methodological approaches can be used to assess the functional consequences of GPR1 genetic variants?

Genetic variations in GPR1 may lead to differential responses to therapeutics . To assess these functional consequences, researchers can employ a multi-faceted approach:

• Identification of variants:

  • Next-generation sequencing to identify GPR1 variants in population cohorts

  • Bioinformatic analysis to predict functional impacts using tools like PolyPhen-2, SIFT

• In vitro functional characterization:

  • Site-directed mutagenesis to introduce specific variants into GPR1 expression constructs

  • Stable cell lines expressing variant GPR1 receptors

  • Comparative signaling assays measuring:

    • Ligand binding affinity using radioligand binding

    • G protein coupling efficacy

    • β-arrestin recruitment kinetics

    • Receptor internalization rates

    • Downstream signaling activation (ERK, Akt pathways)

• Structural analysis:

  • Molecular modeling of variants based on existing cryo-EM structures

  • Molecular dynamics simulations to assess conformational changes induced by mutations

  • Analysis of how variants might disrupt the "two-site" binding model of chemerin

• Systems biology approaches:

  • Transcriptomic analysis of cells expressing variant GPR1 receptors

  • Phosphoproteomic analysis to identify altered signaling pathways

  • Network analysis to identify compensatory mechanisms

This comprehensive approach allows researchers to understand how specific GPR1 variants might alter receptor function and potentially contribute to disease states or differential drug responses.

How can molecular dynamics simulations enhance our understanding of GPR1 activation mechanisms?

Molecular dynamics (MD) simulations have become invaluable tools for studying GPCR activation, including GPR1. Recent research has demonstrated several key applications :

• Binding pocket dynamics:

  • MD simulations can reveal conformational changes in the binding pocket upon ligand binding

  • Identification of key residues that stabilize ligand-receptor interactions

  • Analysis of water molecule networks that may mediate interactions

• Free energy calculations:

  • Parallel bias metadynamics can estimate the unbinding free energy landscape of ligands

  • For example, research has compared the energetics of C9 peptide versus full-length chemerin binding to GPR1

  • These calculations revealed that removing the β-sheet "lid" formed by full-length chemerin is energetically expensive

• Conformational sampling:

  • Long timescale simulations (multiple 1-μs trajectories) can sample receptor conformations not captured in static structures

  • Time-lagged independent component analysis (TICA) can be used to reduce the dimensionality of the data for visualization

  • This approach allows mapping of high-dimensional free energy landscapes onto meaningful reaction coordinates

• Simulation protocol example from recent GPR1 research :

  • Protonation state assignment using H++ web server at pH 7.4

  • CHARMM36m force field employment

  • Energy minimization and membrane relaxation

  • Multiple independent 1-μs production MD simulations

  • Collection of 50,000 conformations from trajectory ensembles

  • Hydrogen bond identification based on distance and angle cutoffs

For GPR1 specifically, MD simulations have provided insights into why the C9 peptide can activate the receptor and how full-length chemerin enhances interaction through its N-terminal domain, supporting the "two-site" binding model .

What are the best approaches for studying cross-talk between GPR1 and other signaling pathways?

Investigating signaling cross-talk involving GPR1 requires sophisticated experimental approaches:

• Proteomics-based interactome mapping:

  • Proximity labeling methods (BioID, APEX) to identify proteins in close proximity to GPR1

  • Co-immunoprecipitation followed by mass spectrometry

  • BRET/FRET-based interaction screening with candidate pathway components

• Phosphoproteomics:

  • Temporal phosphoproteomic profiling following GPR1 activation

  • Comparison of phosphorylation patterns with and without inhibitors of specific pathways

  • Bioinformatic analysis to identify kinase activation patterns

• Transcriptional profiling:

  • RNA-seq following GPR1 activation in the presence/absence of other pathway modulators

  • ChIP-seq to identify transcription factors activated downstream of GPR1

  • Single-cell RNA-seq to capture cell-to-cell variability in responses

• Advanced imaging techniques:

  • Multi-color live-cell imaging of pathway-specific biosensors

  • Super-resolution microscopy to visualize receptor clustering and co-localization

  • FRET sensors for monitoring second messenger production spatiotemporally

• Mathematical modeling:

  • Ordinary differential equation (ODE) models of GPR1 signaling network

  • Parameter estimation using experimental data

  • Sensitivity analysis to identify key pathway interactions

This multi-faceted approach enables researchers to dissect the complex interactions between GPR1 and other signaling pathways, which is crucial for understanding its physiological roles and potential as a therapeutic target.

What are common challenges in expressing functional recombinant GPR1, and how can they be addressed?

Researchers frequently encounter several challenges when expressing functional recombinant GPR1:

When expressing GPR1, it's advisable to avoid heating the protein before electrophoresis as this may cause aggregation . Additionally, aliquoting the protein to avoid repeated freezing and thawing can help maintain functionality.

The wheat germ expression system with proprietary liposome technology has been successfully used to produce functional human GPR1 , suggesting this could be a good starting point for researchers facing expression challenges.

How can researchers design robust controls for GPR1 signaling experiments?

Designing appropriate controls is crucial for GPR1 signaling experiments:

• Negative controls:

  • Mock-transfected cells lacking GPR1 expression

  • Cells expressing non-functional GPR1 mutants (specific mutations in the binding pocket)

  • Treatment with vehicle solutions matching ligand preparations

• Positive controls:

  • Cells expressing known well-characterized GPCRs (e.g., β2-adrenergic receptor)

  • Treatment with established GPR1 ligands (chemerin) at saturating concentrations

  • Internal assay standards (forskolin for cAMP assays)

• Specificity controls:

  • Dose-response experiments to establish concentration-dependence

  • Competition experiments with unlabeled ligands

  • Use of pathway-specific inhibitors to confirm signaling mechanisms

• Technical controls:

  • Inter-assay calibrators to normalize between experimental runs

  • Temperature and time controls to account for receptor degradation

  • Expression level monitoring (via Western blot or flow cytometry) to normalize for receptor density

• Control for off-target effects:

  • Scrambled peptide controls for peptide ligands

  • Testing ligands on related GPCRs to assess selectivity

  • Parallel screening for activation of unrelated pathways

Implementing these controls will help ensure that observed effects are specifically due to GPR1 activation and not experimental artifacts or off-target activities.

What are the most promising therapeutic applications of GPR1 research?

Based on current understanding of GPR1 biology, several therapeutic areas show particular promise:

• Metabolic disorders:

  • GPR1 plays a role in energy homeostasis through its interaction with chemerin

  • Potential target for obesity and type 2 diabetes, similar to other GPCR targets like GLP-1R

  • Modulation might influence glucose metabolism and insulin sensitivity

• Inflammatory conditions:

  • GPR1's role in chemerin signaling suggests involvement in inflammatory processes

  • Potential applications in autoimmune diseases and chronic inflammation

  • Selective antagonists might reduce inflammatory signaling

• Cancer:

  • GPR1 signaling may influence tumor microenvironment and cancer progression

  • Potential for targeted therapies based on GPR1 expression in certain cancers

  • Opportunities for developing antibody-drug conjugates targeting GPR1

• Neurological disorders:

  • GPR1 acts as a receptor for TAFA1, mediating effects on neuronal stem-cell proliferation and differentiation

  • Potential applications in neurodegenerative diseases and neural development disorders

  • Opportunities for modulating neural stem cell fate

• Personalized medicine approaches:

  • Genetic variations in GPR1 may affect drug responses

  • Genotyping could help predict individual responses to GPR1-targeting therapies

  • Development of variant-specific therapeutics

The recent elucidation of the GPR1 structure bound to chemerin provides crucial insights for structure-based drug design efforts targeting this receptor.

What technological advances might accelerate GPR1 research in the coming years?

Several emerging technologies are likely to significantly impact GPR1 research:

• AI-driven structure prediction and drug design:

  • AlphaFold and RoseTTAFold can predict protein structures with high accuracy

  • Machine learning approaches for virtual screening of potential GPR1 ligands

  • AI-guided optimization of lead compounds targeting specific GPR1 conformations

• Advanced cryo-EM techniques:

  • Improved resolution for membrane protein structures

  • Time-resolved cryo-EM to capture intermediate states during activation

  • Smaller sample requirements enabling studies of challenging variants

• Single-molecule imaging and analysis:

  • Super-resolution microscopy of individual GPR1 molecules in living cells

  • Single-molecule FRET to monitor conformational changes upon activation

  • Tracking of individual receptor-ligand interactions in real-time

• Genome editing technologies:

  • CRISPR-Cas9 for precise introduction of GPR1 variants

  • Base editing for specific nucleotide modifications

  • Prime editing for introducing complex modifications without double-strand breaks

• Organoid and microphysiological systems:

  • Patient-derived organoids for testing GPR1-targeting compounds

  • Organ-on-chip models incorporating GPR1-expressing cells

  • Systems allowing for assessment of tissue-specific GPR1 functions

• Advanced computational methods:

  • Enhanced sampling techniques for MD simulations

  • Markov state modeling of GPR1 conformational dynamics

  • Quantum mechanics/molecular mechanics (QM/MM) for detailed binding studies

These technological advances promise to deepen our understanding of GPR1 biology and accelerate the development of therapeutics targeting this receptor system.